Beam Therapeutics Has Initiated A Search For A New CFO After Terry-Ann Burrell Shared Plans To Depart On August 9 To Join JPMorgan Chase
Beam Therapeutics Has Initiated A Search For A New CFO After Terry-Ann Burrell Shared Plans To Depart On August 9 To Join JPMorgan Chase
beam therapeutics在Terry-Ann Burrell宣布计划于8月9日离职加入摩根大通后，开始寻找新的首席财务官。
Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that its chief financial officer, Terry-Ann Burrell, will be leaving the company effective August 9, 2024 to pursue a new opportunity as vice chairman of investment banking at JPMorgan Chase. As part of a transition process, the company has initiated a search for a successor.
生物技术公司Beam Therapeutics Inc. （纳斯达克：BEAM）通过碱基编辑开发精准基因药物，今天宣布，其首席财务官Terry-Ann Burrell将于2024年8月9日离开公司，担任摩根大通投资银行的副主席一职。作为过渡的一部分，公司已经启动寻找继任者的搜索。